Navigation Links
Research shows HPV testing offers women protection for twice as long as smear testing
Date:5/14/2008

The long term findings of a study carried out at Hammersmith hospital reveal that testing for Human Papilloma Virus (HPV) can be twice as effective at protecting women from developing cervical abnormalities as smear testing. Results of the research led by Professor Jack Cuzick of Barts and The London School of Medicine and Dentistry - are published today (Thursday, 15 May 2008) in the International Journal of Cancer.

Nearly 3,000 women aged 35+ were recruited into the study between April 1994 and September 1997. They were asked to participate in a study in which HPV testing would be performed in addition to cytology (smear test) whilst attending their GP practice (40 practices were involved in the trial) for a routine cervical smear. Women who had previously been treated for cervical intra-epithelial neoplasia (CIN) changes to cells in the cervix that can develop into cancer or had experienced any cervical abnormality within the previous 3 years, were excluded from the study.

All women tested were followed up passively using data from the national computerised system that records all smears and their results the Open-Exeter system. Women with a smear history indicating the need for colposcopy a more thorough examination of the cervix were investigated further to determine whether the colposcopy and biopsy were performed, and what the resultant outcome was. Passive follow-up was complete for all women by early 2005.

Results showed that the risk of developing cervical abnormalities at 1, 5, and 9 years after a normal smear test was 0.33 per cent, 0.83 per cent, and 2.20 per cent respectively, with those odds significantly reduced after a negative HPV test - 0.19 per cent, 0.42 per cent, and 1.88 per cent.

Professor Jack Cuzick said: Not only does the research confirm that HPV testing detects more disease at each smear, it shows that this approach offers women excellent protection from cervical abnormalities for at least 6 years after a negative test, compared to protection from a normal smear test which begins to wane after about 3 years. This suggests that the screening interval can be safely extended to at least 6 years with HPV testing. These data provide more support for replacing screening based on abnormal cells, with a more sensitive test based on screening for the human papillomavirus.


'/>"/>

Contact: Alex Fernandes
a.fernandes@qmul.ac.uk
020-788-27910
Queen Mary, University of London
Source:Eurekalert

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. Children of depressed moms do better when dad is involved, SLU researcher finds
3. UCLA researchers identify markers that may predict diabetes in still-healthy people
4. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
5. New research shows how chronic stress worsens neurodegenerative disease course
6. New research explores newborn in-hospital weight loss
7. Research may unlock mystery of autisms origin in the brain
8. Bipolar disorder relapses halved by Melbourne researchers
9. HIVs impact in Zimbabwe explored in new research
10. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
11. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology: